Effects of sildenafil on rat irritable bowel syndrome

Therapy

Volumn 2, Issue 2, 2005, Pages 237-242

  Zamani, Mohammad Jafar ^a   Sharifzadeh, Mohammad ^a   Rezaie, Ali ^a   Mashayekhi, Fereshteh ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cyclic AMP; Cyclic GMP; Fecal excretion; Gastric emptying; Irritable bowel syndrome; Sildenafil; Small bowel transit; Total antioxidant capacity

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; MEBEVERINE; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; PROKINETIC AGENT; SCOPOLAMINE BUTYL BROMIDE; SILDENAFIL; TRIMEBUTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; INCIDENCE; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LARGE INTESTINE; MALE; NONHUMAN; PATHOPHYSIOLOGY; RAT; SMALL INTESTINE; STOMACH EMPTYING; STRESS;

EID: 16244376223     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.2.237     Document Type: Article

References (34)

1. Mayer EA, Naliboff BD, Chang L, Coutinho SV. Stress and irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G519-G524 (2001).
2. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 47, 225-235 (2002).
3. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther. 17, 643-650 (2003).
4. Longstreth GF. Irritable bowel syndrome - a multibillion-dollar problem. Gastroenterology 109, 2029-2031 (1995).
5. Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol. Latinoam. 25, 137-144 (1995).
6. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 100, 998-1005 (1991).
7. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the lature on symptom and psychosocial factors. Am. J. Gastroenterol. 96, 1340-1349 (2003).
8. van Zanten SV. Diagnosing irritable bowel syndrome. Rev. Gastroenterol. Disord. 3, S12-S17 (2003).
9. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 97, S7-S26 (2002).
10. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 15, 355-361 (2001).
11. Cartledge J, Eardley I. Sildenafil. Expert Opin. Pharmacother. 1, 137-147 (1999).
12. Boyce EG, Umland EM. Sildenafil citrate: a therapeutic update. Clin. Ther. 23, 2-23 (2001).
13. Bortolotti M, Lopilato C, Porrazzo G, Miglioli M. Effect of sildenafil on esophageal motility. Gastroenterology 118, A4770-A4770 (2000).
14. Bortolotti M, Pandolfo N, Giovannini M, Mari C, Miglioli M. Effect of sildenafil on hypertensive lower oesophageal sphincter. Eur. J. Clin. Invest. 32, 682-685 (2002).
15. de Rosalmeida MC, Saraiva LD, da Graca JR et al. Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Dig. Dis. Sci. 48, 2064-2068 (2003).
16. Fritz E, Hammer J, Schmidt B, Eheter AJ, Hammer HF. Stimulation of the nitric oxide-guanosine 3′,5′-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. Am. J. Gastroenterol. 98, 2253-2560 (2003).
17. Williams CL, Villar RG, Peterson JM, Burks TF. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology 94, 611-621 (1998).
18. Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn J. Pharmacol. 86, 281-288 (2001).
19. Iris F, Benzi F, Strain S. Ferric reducing antioxidant assay. Method Enzymol. 292, 15-27 (1999).
20. Izbeki F, Wittmann T, Csati S, Jeszenszky E, Lonovics J. Opposite effects of acute and chronic administration of alcohol on gastric emptying and small bowel transit in rat. Alcohol 36, 304-308 (2001).
21. Tache Y, Maeda-Hagiwara M, Turkelson CM. Central nervous system action of corticotropin-releasing factor to inhibit gastric emptying in rats. Am. J. Physiol. 253, G241-G245 (1987).
22. Glossmann H, Petrischor G, Bartsch G. Molecular mechanisms of the effects of sildenafil (VIAGRA). Exp. Gerontol. 34, 305-318 (1999).
23. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J. Cell Physiol. 184, 409-420 (2000).
24. Suzuki E, Kageyama H, Nakaki T, Kanba S, Inoue S, Miyaoka H. Nitric oxide induced heat shock protein 70 mRNA in rat hypothalamus during acute restraint stress under sucrose diet. Cell Mol. Neurobiol. 23, 907-915 (2003)
25. Sanches DB, Steiner AA, Branco LG. Involvement of neuronal nitric oxide synthase in restraint stress-induced fever in rats. Physiol. Behav. 75, 261-266 (2002).
26. Luo ZD, Cizkova D. The role of nitric oxide in nociception. Curr. Rev. Pain 4, 459-466 (2000).
27. Abdollahi M, Nikfar S, Abdoli N. Potentiation by nitric oxide synthase inhibitor and calcium channel blocker of aspartame-induced antinociception in the mouse formalin test. Fundam. Clin. Pharmacol. 15, 117-123 (2001).
28. Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Torres-Lopez JE, Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. Eur. J. Pharmacol. 418, 195-200 (2001).
29. Bortolotti M, Mari C, Lopilato C, La Rovere L, Miglioli M. Sildenafil inhibits gastroduodenal motility. Aliment. Pharmacol. Ther. 15, 157-161 (2001).
30. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci. 49(11-12), 1752-1757 (2004).
31. Schempp H, Toth A, Weiser D, Elstner EF. Antioxidative properties of Iberis amara extracts in biochemical model reactions. Arzneimittelforschung 53, 568-577 (2003).
32. Abdollahi M, Chan TS, Subrahmanyam V, O'Brien PJ. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol. Cell Biochem. 252, 205-211 (2003).
33. Abdollahi M, Fooladian F, Emami B, Zafari K, Bahreini-Moghadam A. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum. Experim. Toxicol. 22, 587-592 (2003).
34. Abdollahi M, Bahreini-Moghadam A, Emami B, Fooladian F, Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp. Biochem. Physiol. Toxicol. Pharmacol. 135, 331-336 (2003).